A Phase I, open-label study of SIRPα antagonist (BI 765063) in combination with ezabenlimab alone or with BI 836880, chemotherapy or cetuximab in patients with recurrent/metastatic HNSCC or HCC (NCT05249426)
AE, adverse event; DoR, duration of response; DC, disease control; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; OR, objective response; PFS, progression-free survival; R, randomization; R/M, recurrent or metastatic; SIRPα, signal regulatory protein α.